Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.01 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.